Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

The challenge persists, but, with a renewed focus from regulatory bodies and trial sponsors alike on improving enrolment ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

In the era of precision medicine, life sciences teams can utilise real-world data (RWD) to generate actionable real-world evidence (RWE) about how to develop and deliver more targeted medications ...

In an era where healthcare advancements are at their peak, an often overlooked, yet critical, aspect is the management of pharmaceutical waste. This intricate balance of cost, compliance, and ...

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and Wales. Final draft ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

There is a lot, and I mean a lot, of discussion right now about the potential for artificial intelligence (AI) to transform the pharmaceutical industry (as, indeed, there is across all industries).

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to ...